Prognostic Value of PtcO2 in Patients With COVID-19

Recruiting

• Conditions: COVID-19 Acute Respiratory Distress Syndrome
• Interventions: Other: outcome; Other: Subtype of COVID-19

• Registration Number: NCT05682612
• Lead Sponsor: Southeast University, China

Brief Summary

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Detailed Description

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission. Attention should be paid to patients over 65 years of age who have severe underlying diseases (cancer, respiratory diseases, cardiovascular and cerebrovascular diseases, chronic renal failure, autoimmune deficiency diseases, etc.) and have not completed the whole course of vaccine, and such patients often have abnormal oxygen tolerance, that is, a significant decrease in skin finger pulse oxygen saturation (SpO2) can occur after daily activities. Basal SpO2 at admission is often associated with prognosis, but it is difficult to differentiate prognosis from responsiveness to treatment by changes in SpO2 after oxygen therapy is administered clinically. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Study Timeline

• Study First Submitted: 2023-01-01
• Study Start: 2023-01-09
• Study First Submitted QC: 2023-01-10
• Study First Posted: 2023-01-12
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-09
• Last Update Posted: 2023-10-12
• Primary Completion: 2023-12-01
• Study Completion: 2023-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest)；

Exclusion Criteria

• Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Survivors	outcome	Survivors of COVID-19 induced respiratory failure
Nonsurvivors	Subtype of COVID-19	Nonsurvivors of COVID-19 induced respiratory failure
Nonsurvivors	outcome	Nonsurvivors of COVID-19 induced respiratory failure
Survivors	Subtype of COVID-19	Survivors of COVID-19 induced respiratory failure

Primary Outcome Measures

Name	Time	Method
Level of Transcutaneous partial pressure of oxygen	up to 30 days	Level of Transcutaneous partial pressure of oxygen

Secondary Outcome Measures

Name	Time	Method
Level of Transcutaneous partial pressure of oxygen/FiO2	up to 30 days	Level of Transcutaneous partial pressure of oxygen/FiO2

Trial Locations

Locations (1)

Zhongda hospital; 🇨🇳 Nanjing, Jiangsu, China